The ratio of intra-tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer

Journal of Surgical Oncology

Volumn 104, Issue 7, 2011, Pages 728-733

  Kim, Hyoung Il ^a   Kim, Haeryoung ^b   Cho, Hyoung Won ^a   Kim, Sang Yong ^a   Song, Ki Jun ^a   Hyung, Woo Jin ^a   Park, Chung Gyu ^c   Kim, Choong Bai ^a  

^a Yonsei University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

regulatory T lymphocytes; stomach neoplasms; survival; tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GRANZYME B; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARDIA CARCINOMA; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HELPER CELL; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; CARDIA; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 80255138234     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22038     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. von Rahden BH, Stein HJ, Siewert JR,: Surgical management of esophagogastric junction tumors. World J Gastroenterol 2006; 12: 6608-6613. (Pubitemid 44794936)
3. Dunn GP, Old LJ, Schreiber RD,: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148. (Pubitemid 39094044)
4. Clemente CG, Mihm MC, Jr., Bufalino R, et al.: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-1310. (Pubitemid 26102328)
5. Pages F, Berger A, Camus M, et al.: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666. (Pubitemid 41817714)
6. Zhang L, Conejo-Garcia JR, Katsaros D, et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213. (Pubitemid 36077915)
7. Cho Y, Miyamoto M, Kato K, et al.: CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003; 63: 1555-1559. (Pubitemid 36373643)
8. Sinicrope FA, Rego RL, Ansell SM, et al.: Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137: 1270-1279.
9. Petersen RP, Campa MJ, Sperlazza J, et al.: Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006; 107: 2866-2872. (Pubitemid 44937041)
10. Fu J, Xu D, Liu Z, et al.: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339. (Pubitemid 46890865)
11. Curiel TJ, Coukos G, Zou L, et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949. (Pubitemid 39273735)
12. Yu P, Fu YX,: Tumor-infiltrating T lymphocytes: Friends or foes? Lab Invest 2006; 86: 231-245. (Pubitemid 43276955)
13. Bates GJ, Fox SB, Han C, et al.: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-5380. (Pubitemid 46623168)
14. Perrone G, Ruffini PA, Catalano V, et al.: Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008; 44: 1875-1882.
15. Hori S, Nomura T, Sakaguchi S,: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061. (Pubitemid 36222930)
16. Sakaguchi S, Sakaguchi N, Shimizu J, et al.: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32. (Pubitemid 33070205)
17. Edge SB, Byrd DR, Compton CC, et al.: AJCC cancer staging manual. New York: Springer-Verlag; 2009.
18. Gao Q, Qiu SJ, Fan J, et al.: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-2593. (Pubitemid 47041232)
19. Song J, Lee HJ, Cho GS, et al.: Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: A multicenter retrospective analysis of 1,417 patients. Ann Surg Oncol 2010; 17: 1777-1786.
20. Haas M, Dimmler A, Hohenberger W, et al.: Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 2009; 9: 65.
21. Mizukami Y, Kono K, Kawaguchi Y, et al.: Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 2008; 98: 148-153.
22. Shen Z, Zhou S, Wang Y, et al.: Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol 2010; 136: 1585-1595.
23. Zhou G, Lu Z, McCadden JD, et al.: Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 2004; 200: 1581-1592. (Pubitemid 40094182)
24. Ghiringhelli F, Menard C, Puig PE, et al.: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648. (Pubitemid 46348738)
25. Dannull J, Su Z, Rizzieri D, et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-3633. (Pubitemid 43121851)